- Home
- BCAX
BCAX
BICARA THERAPEUTICS INC
as 03-28-2025 4:00pm EST
Stocks
Bicara Therapeutics Inc is a clinical-stage biopharmaceutical company bringing transformative bifunctional therapies to patients with solid tumors. Its program ficerafusp alfa is a bifunctional antibody that combines two clinically validated targets, an epidermal growth factor receptor, or EGFR, directed monoclonal antibody with a domain that binds to human transforming growth factor beta, or TGF-b.
| Founded: | 2018 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 670.9M | IPO Year: | 2024 |
| Target Price: | $34.20 | AVG Volume (30 days): | 608.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -4.05 | EPS Growth: | N/A |
| 52 Week Low/High: | $11.10 - $28.09 | Next Earning Date: | 03-27-2025 |
| Revenue: | N/A | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
Latest BICARA THERAPEUTICS INC News
BCAX Breaking Stock News: Dive into BCAX Ticker-Specific Updates for Smart Investing
GlobeNewswire
2 days ago
Bicara Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update
GlobeNewswire
4 days ago
Bicara Therapeutics Announces Upcoming Presentations at AACR Annual Meeting 2025
Simply Wall St.
17 days ago
Companies Like Bicara Therapeutics (NASDAQ:BCAX) Are In A Position To Invest In Growth
GlobeNewswire
a month ago
Bicara Therapeutics to Present at the TD Cowen 45th Annual Health Care Conference
GlobeNewswire
2 months ago
Bicara Therapeutics Announces First Patients Enrolled in FORTIFI-HN01, a Pivotal Phase 2/3 Clinical Trial of Ficerafusp Alfa in 1L Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
MT Newswires
2 months ago
Wedbush Initiates Coverage on Bicara Therapeutics With Outperform, $31 Price Target
GlobeNewswire
2 months ago
Bicara Therapeutics Presents Phase 1/1b Dose Expansion Results with Ficerafusp Alfa in Advanced Squamous Cancer of the Anal Canal at the 2025 ASCO Gastrointestinal Cancers Symposium
Clinical Trials Arena
3 months ago
Early success for MBX in Phase I trial of GLP-1RA for hypoglycaemia
Compare BCAX vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "BCAX BICARA THERAPEUTICS INC - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.